Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methylprednisolone in multiple sclerosis exacerbation: changes in CSF parameters.

T J Anderson1, I M Donaldson, J M Sheat

  • 1Christchurch Hospital, New Zealand.

Australian and New Zealand Journal of Medicine
|December 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DNA hypermethylation/boundary control loss identified in retinoblastomas associated with genetic and epigenetic inactivation of the <i>RB1</i> gene promoter.

Epigenetics·2020
Same author

Evaluation of a surgical task sharing training programme's logbook system in Sierra Leone.

BMC medical education·2019
Same author

The 'bloody Moloch': Osler and van Helmont on bloodletting.

The journal of the Royal College of Physicians of Edinburgh·2017
Same author

van Helmont's proposal for a randomised comparison of treating fevers with or without bloodletting and purging.

The journal of the Royal College of Physicians of Edinburgh·2016
Same author

Smellie & Hunter: Atlases of the gravid uterus. Part 2.

The journal of the Royal College of Physicians of Edinburgh·2016
Same author

Smellie and Hunter: Atlases of the gravid uterus. Part 1.

The journal of the Royal College of Physicians of Edinburgh·2016

Intravenous methylprednisolone effectively reduced immunoglobulin G (IgG) and albumin levels in patients with multiple sclerosis (MS). While initial treatment improved clinical status, repeat courses showed diminished effects on the CSF IgG index.

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Pharmacology

Background:

  • Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
  • Acute neurological deterioration in MS often necessitates treatment to reduce inflammation and restore function.
  • Intravenous methylprednisolone is a common treatment for acute MS exacerbations.

Purpose of the Study:

  • To evaluate the effects of intravenous methylprednisolone on cerebrospinal fluid (CSF) and serum parameters in MS patients.
  • To compare the efficacy of initial versus repeat courses of methylprednisolone treatment.
  • To assess the correlation between changes in CSF parameters and clinical improvement.

Main Methods:

  • Twenty-six patients with multiple sclerosis received 45 courses of intravenous methylprednisolone (7-day daily infusions).

Related Experiment Videos

  • CSF and serum samples were analyzed for immunoglobulin G (IgG) and albumin levels, and CSF IgG synthesis rate.
  • Clinical status was assessed before and after treatment; initial and repeat courses were compared.

    • Main Results:

    • Both initial and repeat methylprednisolone courses significantly reduced CSF IgG, serum IgG, CSF albumin, and serum albumin levels.
    • CSF IgG synthesis rate decreased significantly with treatment.
    • The CSF IgG index showed a significant reduction after the initial course but not after repeat courses. Oligoclonal bands resolved in three patients. Clinical improvement occurred in 36 patients (30 definite, 6 possible).

    Conclusions:

    • Intravenous methylprednisolone effectively reduces key inflammatory markers in MS patients during acute exacerbations.
    • While initial treatment significantly impacts the CSF IgG index and clinical status, repeat courses may have a diminished effect on the IgG index.
    • Pre-treatment CSF IgG synthesis status does not predict clinical response to methylprednisolone.